Almost half of clinical trials conducted between April and November 2020 were disrupted by slow enrollment, according to life sciences analytics firm GlobalData.

GlobalData reports that the total number of disrupted clinical trials grew six-fold in the second quarter, from about 200 in April to more than 1,200 in June, with 35 percent of clinical trials suspending enrollment and 16 percent delaying startup as a result of the pandemic.

The firm says the number of trials disrupted by COVID-19 peaked in the first week of June and began a steady rate of recovery into November. Delayed initiation of trials has remained essentially flat since June.